- Home
- GIXI vs BLRX Comparison
GIXI vs BLRX Comparison
Compare GIXI & BLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
N/A
Current Price
$4.31
N/A
Current Price
$2.35
Company Overview
Basic Information| Metric | GIXI | BLRX |
|---|---|---|
| Founded | 1978 | 2003 |
| Country | Israel | Israel |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.6M | 12.0M |
| IPO Year | N/A | 2010 |
Fundamental Metrics
Financial Performance| Metric | GIXI | BLRX |
|---|---|---|
| Price | $4.31 | $2.35 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 24.1K | 12.3K |
| Earning Date | 11-30-2026 | 08-31-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $37.33 |
| Revenue Next Year | N/A | $37.06 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.39 | $2.15 |
| 52 Week High | $6.25 | $4.56 |
Technical Indicators
Market Signals| Indicator | GIXI | BLRX |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 37.71 |
| Support Level | N/A | $2.18 |
| Resistance Level | N/A | $2.51 |
| Average True Range (ATR) | 0.00 | 0.11 |
| MACD | 0.00 | -0.01 |
| Stochastic Oscillator | 0.00 | 6.06 |
Price Performance
Historical Comparison GIXI
BLRX
About BLRX BioLineRx Ltd.
BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has a legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.